PULS's board consists of extensive scientific, industrial, business, legal and financial experience and expertise.
MBA, Bove has a long experience from sales, strategic business development and commercial operations with previous positions as Senior Director Global Marketing at Ferring Pharmaceuticals A/S, Vice President Global Marketing at Coloplast A/S, Innovation Officer at Lund University Diabetes Centre (LUDC) and Senior Investment Manager and Head of Life Science at Copenhagen Capacity. Bove is currently CEO at EIT Health C.V.
Professor of Orthopedic Surgery, Sahlgrenska Academy, University of Gothenburg, Sweden. Author or co-author of more than 60 publications.
MD, PhD, Senior Consultant and Head of the Endocrine & Obesity Department at Queen Silvia Children's Hospital and also Professor and Senior Lecturer at the University of Gothenburg. Dahlgren is Director of Gothenburg Pediatric Growth Research Center and has published 70 peer-reviewed articles mainly in the field of growth disorders and childhood obesity.
MD, PhD, Professor/consultant in Cardiology/ Interventional cardiology (PCI), Head of Dept. of Cardiology, Lund University Hospital. Head of the research unit Molecular Cardiology, a leading group in cardiovascular research focusing on extracellular nucleotides and their receptors.
Karl Olov Fagerström
PhD, Licensed Psychologist, specialized in Behavioural Medicine and world leading expert in smoking cessation and nicotine dependence. WHO awarded for “outstanding work in the nicotine and tobacco field”. Published 145 papers in peer reviewed journals and is the first author of about 85. Founder of Niconovum AB, sold to Reynolds Inc. in 2009.
M.Sc., chairman of Trioplast Industrier AB, Diaprost AB and board member in FredAx AB, Logstor AS, Marco AB and Mobilis Kapitalförvaltning AB. Former CEO of Perstorp AB and chairman of P.U.L.S. AB.
M.Sc. in Molecular Biology, PhD in Medicine (2013). Currently completing her MD training at the University of Gothenburg. Past and current research at the Sahlgrenska Academy at the University of Gothenburg is focused on the concept of personalized medicine (i.e. pharmacogenetics) within the field of classical endocrinology, and gene regulation in metabolic disorders. Despite her early stage of scientific career, internationally recognized in her field and has 10 publications in renowned journals including Nature Reviews Endocrinology.
PhD, Director of the Centre for Technology in Medicine and Health (Karolinska Institutet, KTH, Stockholm County Council), Associate Professor (KTH), Head of Clinical Innovation Research Unite (KTH). His research revolves around the processes of innovation in medical technology, the faculty of judgement in venture capital investments in technological development projects and the structuring of innovation processes. He is scientific advisor to Swedish MedTech, the Association for Medical Technology in Sweden, member of the financial board at the Swedish Child Cancer Fund, as well as member of the board at a few minor medical technology companies. Guve has previously been Stockholm Director for the Medical Technology Investment Fund of the Stockholm County Council (LFTP) and assessor at the Swedish Industrial Development Fund (Industrifonden).
Maria Alquist Hegbrant
MD, Vice President Global Medical & Scientific Support, Senior Medical Director, Gambro. Senior Nephrologist and Internist, broad experience from clinical medicine, medical device and healthcare industry. Served as expert member in the Swedish Foundation for Strategic Research life science grant committees.
M.Sc. in Biomedicine and Toxicology, has more than 30 years of professional experience from regulatory affairs, drug development and business development. Owner and CEO of Scandinavian Regulatory Services AB.
M.Sc., PhD, Professor in Medical and Chemical Microsensors at the Department of Electrical Measurements, Lund Institute of Technology at Lund University. Innovator, founder and board member in several technology companies.
PhD (organic synthesis, pharmaceutical science). Postdoctoral researcher at Centre for Analysis and Synthesis at Lund Institute of Technology at Lund University. The research is focused on the development and synthesis of small sugar molecules to be used in anti-tumor treatment. Former board member in The Research School in Pharmaceutical Sciences (FLÄK), Lund.
Professor of Toxicology at Karolinska Institutet. Presently involved in establishing Swedish Toxicology Sciences Research Center (Swetox). Was until 2012 Vice President and Head of Safety Assessment at Astra and AstraZeneca globally being responsible for all preclinical safety. Was before joining Astra Professor of Biochemical Toxicology at Karolinska Institutet. Has more than 200 publications in the areas of drug metabolism and mechanistic toxicology.
MD, PhD. Research Resident at the Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg. Research field: Pituitary tumours, hormonal replacement therapy and discovering novel tumour markers connected to patient outcome. Co-founder of the Intern Council at Sahlgrenska University Hospital and of the Medical Student Research Program at University of Gothenburg.
MD, PhD, Senior Consultant, Head of Antenatal Health care and Associate Professor, Department of Obstetrics & Gynecology, Skåne University Hospital, specialized in high risk pregnancy. Regional Maternal Health Care Consultant in Skåne, Sweden. Developed national guidelines for antenatal health care. Board member of “International Society of the Study of Hypertension in Pregnancy”. Higher education in Health Economy. More than 20 publications.
MD, Clinical Innovations Fellow at Karolinska Institutet and KTH. Experience from global health/management research through Harvard Center for Health and the Global Environment, in addition to neurological research at University of Gothenburg. Innovator and co-founder of LARA Diagnostics. Former vice president of The Swedish Society of Medicine for young MDs.